Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities.
Morris, Gerwyn, Puri, Basant K, Walker, Adam J et al. · Pharmacological research · 2019 · DOI
Quick Summary
This review examines what goes wrong in the bodies of ME/CFS patients and looks at treatments that might help. Researchers found that ME/CFS involves several biological problems, including inflammation, increased cellular stress, gut problems, and energy production issues. The review highlights five promising supplements—coenzyme Q10, melatonin, curcumin, molecular hydrogen, and N-acetylcysteine—that target these problems, though much more testing is needed.
Why It Matters
ME/CFS lacks established, effective, evidence-based treatments, representing a significant unmet clinical need affecting millions. This review identifies specific biological pathways amenable to targeted intervention and highlights candidate therapeutics based on mechanistic understanding rather than empiricism, potentially redirecting research toward more effective treatments.
Observed Findings
ME/CFS patients show evidence of pro-inflammatory states
Multiple patients demonstrate oxidative and nitrosative stress markers
Gut mucosal barrier dysfunction has been documented in ME/CFS subgroups
Mitochondrial dysfunction and dysregulated bioenergetics are present in at least some patients
Coenzyme Q10, melatonin, curcumin, molecular hydrogen, and N-acetylcysteine show theoretical mechanistic promise in preliminary studies
Inferred Conclusions
ME/CFS involves multiple, interconnected pathophysiological abnormalities rather than a single mechanism
Therapeutic strategies targeting these specific pathways offer potential alternatives to current ineffective approaches
Integrated interventions addressing multiple mechanisms simultaneously may be more effective than single-target approaches
Robust clinical trials of the identified candidate therapeutics are warranted to translate mechanistic insights into patient benefit
Remaining Questions
Which pathophysiological abnormalities are present in all ME/CFS patients versus disease subsets, and which are primary drivers versus secondary consequences?
What This Study Does Not Prove
This systematic review does not prove that any of the proposed supplements are clinically effective in ME/CFS patients—the evidence reviewed remains preliminary and mostly preclinical. The review cannot establish causation between the identified pathophysiological abnormalities and ME/CFS symptoms, nor can it determine which abnormalities are primary versus secondary. Clinical efficacy requires rigorous randomized controlled trials, which are largely absent for these interventions.
Tags
Method Flag:PEM Not DefinedWeak Case DefinitionExploratory Only
Do any of the proposed supplements (CoQ10, melatonin, curcumin, molecular hydrogen, N-acetylcysteine) show clinical efficacy in rigorous randomized controlled trials?
Should treatment approaches be personalized based on individual pathophysiological profiles, and how can such profiling be practically implemented?
Can combination therapies targeting multiple pathways simultaneously achieve better outcomes than single-agent interventions?